SCHEMBL4396535

SCHEMBL4396535

Cc1nc2ccccc2nc1C([NH])=O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.52
ALDH1A1 P00352 5/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
KDM4E B2RXH2 3/20 0.47
CYP1A2 P05177 2/20 0.47
PDE10A Q9Y233 1/20 0.44
HSD17B10 Q99714 2/20 0.42
TP53 P04637 1/20 0.42
HTT P42858 2/20 0.41
LMNA P02545 1/20 0.41
MAPK1 P28482 1/20 0.41
HPGD P15428 2/20 0.41
GAA P10253 2/20 0.41
STAT3 P40763 1/20 0.41
NUDT1 P36639 1/20 0.41
GPR3 P46089 1/20 0.41
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29670121 0.82 ALDH1A1 (0.72) MAPTALDH1A1SMN1; SMN2KDM4ECYP1A2
SCHEMBL2056931 0.82 ALDH1A1 (0.72) MAPTALDH1A1SMN1; SMN2KDM4ECYP1A2
SCHEMBL4833903 0.82 MAPT (0.54) MAPTALDH1A1SMN1; SMN2KDM4ECYP1A2
SCHEMBL6387026 0.80 MAPT (0.52) MAPTALDH1A1SMN1; SMN2KDM4ECYP1A2
SCHEMBL14734375 0.79 MAPT (0.47) MAPTALDH1A1SMN1; SMN2KDM4ECYP1A2
SCHEMBL14734446 0.79 ALDH1A1 (0.47) MAPTALDH1A1SMN1; SMN2KDM4ECYP1A2
SCHEMBL27937220 0.78 MAPT (0.48) MAPTALDH1A1SMN1; SMN2KDM4ECYP1A2
SCHEMBL6386134 0.77 SMN1; SMN2 (0.56) MAPTALDH1A1SMN1; SMN2KDM4ECYP1A2
SCHEMBL11177962 0.77 HTT (0.58) MAPTALDH1A1SMN1; SMN2KDM4ECYP1A2
SCHEMBL10574225 0.77 MAPT (0.48) MAPTALDH1A1SMN1; SMN2KDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8344181-B2 Obesity, type 2 diabetes, hyperlipidemia, hypertension, arteriosclerosis, coronary heart diseases JANSSEN PHARMACEUTICA N.V. (BE) 2013-01-01 US disclosed
EP-1796657-B1 N-2 ADAMANTANYL-2-PHENOXY-ACETAMIDE DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2009-12-23 EP disclosed
US-20080064693-A1 N-2 Adamantanyl-2-Phenoxy-Acetamide Derivatives as 11-Beta Hydroxysteroid Dehydrogenase Inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2008-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064693-A1 N-2 Adamantanyl-2-Phenoxy-Acetamide Derivatives as 11-Beta Hydroxysteroid Dehydrogenase Inhibitors HSD3B1, HSD3B2, HSD11B1 MAPT 4781/4885ALDH1A1 410/4885SMN1; SMN2 4268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.